Smith & Nephew Stock Price, News & Analysis

Smith+Nephew (LSE:SN, NYSE:SNN) announced a new publication highlighting that its PICO Single Use Negative Pressure Wound Therapy System (sNPWT) reduces surgical site infections (SSIs) by 63%, seroma by 77%, and dehiscence by 30%. The systematic review covered 29 studies with 5,614 patients, demonstrating the therapy's efficiency across various surgical specialties. The PICO sNPWT also decreases hospital stay length by nearly 2 days, potentially benefiting healthcare systems significantly. This evidence supports PICO therapy for preventing surgical complications effectively.

Smith+Nephew (NYSE: SNN) has successfully launched a new inventory automation solution in partnership with Movemedical in the US. This platform aims to simplify field sales operations for better inventory management, ensuring timely product delivery to customers. The solution enhances logistics and real-time data access, empowering sales teams to meet customer needs effectively. Smith+Nephew integrated this system across its entire US Orthopaedic sales force in just over a week, highlighting its operational efficiency.

Smith+Nephew (LSE:SN, NYSE:SNN) has announced exceptional clinical outcomes for its total hip arthroplasty (THA) portfolio, achieving the highest implant survivorship of 98.46% at ten years in the National Joint Registry for England, Wales, and Northern Ireland. Their POLAR3 Total Hip Solution also boasts a 72% lower revision risk compared to the class average. Additionally, the Australian Orthopaedic Association Registry reported a 94.5% survivorship at 15 years with the proprietary OXINIUM Technology, which reduces revision risk by 39-41% compared to traditional options.

Smith+Nephew (NYSE:SNN) has launched RI.INSIGHTS, a pioneering platform aimed at enhancing robotics-assisted surgeries. This tool allows orthopedic surgeons to benchmark their surgical experiences against peers and utilize intra and post-operative data to improve patient outcomes. The platform, part of the Real Intelligence portfolio, aims to drive advancements in digital health and robotics surgery. Currently available on a limited basis, a full commercial release is planned for 2021. Smith+Nephew generated $5.1 billion in sales in 2019, emphasizing its commitment to innovation in orthopedic technology.

Smith+Nephew (NYSE:SNN) announced positive two-year follow-up results from the STITCH Study for its NOVOSTITCH Meniscal Repair Systems. This first-of-its-kind trial demonstrated an impressive clinical success rate of 82.6%, with significant improvements in all Patient Reported Outcome Measures (PROMs) at p<0.001. Complete meniscal healing was observed in 100% of patients evaluated at six months. The study emphasizes a shift towards meniscal repair, which could prevent long-term complications like osteoarthritis associated with meniscectomy. The NOVOSTITCH system offers innovative solutions for complex meniscal tears.

Smith+Nephew (NYSE:SNN) has enhanced its ARIA digital care management platform with new tools: ARIA SiteSelect and ARIA Optimized Recovery Pathways. These innovations aim to assist clinicians in accurately determining suitable outpatient surgery candidates and standardizing total joint care pathways for improved post-operative outcomes. Utilizing patient history and lifestyle data, ARIA SiteSelect helps identify optimal surgical sites, while the 90-day recovery pathways are designed to reduce complications and enhance patient mobility post-surgery.

Smith+Nephew (NYSE: SNN) has announced the upcoming launch of ARIA Home PT, a remote physical therapy module for its ARIA digital care management platform, set for early 2021. This module includes a virtual coaching system utilizing 3D motion capture technology, aiming to enhance patient recovery and expand access to post-acute care. Telehealth functionalities will follow soon after. The initiative is part of Smith+Nephew's investment in its Positive Connections program, addressing the growing demand for digital health solutions.

Smith+Nephew (NYSE:SNN) has been awarded Most Innovative at the 2020 Gartner Communications Awards for its T.I.M.E. clinical decision support tool (CDST), which addresses the lack of consistent wound assessment practices among specialists. Developed through collaboration with international experts, the tool aims to improve clinical outcomes by standardizing care delivery. The campaign has seen significant customer engagement, generating multiple publications and a consensus document by the World Union of Wound Healing Societies. This recognition highlights Smith+Nephew’s commitment to enhancing patient care and stakeholder engagement.

Smith+Nephew (NYSE:SNN) has partnered with Avail Medsystems to implement remote collaboration services in operating rooms. This innovative approach allows healthcare professionals to support procedures without being physically present, enhancing efficiency in hospitals and ASCs where space is limited. The Avail System features HD cameras and a split-screen display for real-time interaction. Smith+Nephew aims to improve surgical education and access to expertise while reducing capital investments. This initiative aligns with their mission to enhance medical technology and demonstrates adaptability in a changing healthcare environment.